Literature DB >> 11350974

Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1.

K Engelmann1, S E Baldus, F G Hanisch.   

Abstract

This study shows for the first time that the tandemly repeated icosapeptide of human MUC1 underlies a genetic sequence polymorphism at three positions (underlined): PDTRPAPGSTAPPAHGVTSA. The concerted replacement DT-->ES (sequence variation 1) and the single replacements P-->Q (sequence variation 2), P-->A (sequence variation 3), and P-->T (sequence variation 4) were identified by sequencing of polymerase chain reaction products and studied by minisatellite variant repeat analysis for their incidence and topology in the 5' and 3' peripheral regions of the variable number of tandem repeats domain. Minisatellite variant repeat analyses were performed with 27 individual samples of genomic DNA from human cells and tissues covering 30-60% of the domain. Within the peripheral regions, sequence variations 1-4 occur at high incidence and show a nearly constant repeat topology in all individual normal and tumor samples. Also, individuals who were non-Caucasian or of different ethnic background were found to have the same set of replacements with identical topology. The repeat variant 1 replacing the established tumor target motif DTR with ESR was found in all individuals and appears predominantly in repeat clusters (diads and triads). The largely constant topology of variant repeats is interpreted by the assumption that the variable number of tandem repeats domain has evolved as a recent expansion of sequence variable super-repeats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350974     DOI: 10.1074/jbc.M103187200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

2.  Hypervariability of the membrane-associated mucin and cancer marker MUC1.

Authors:  Joanna C Fowler; Ana S Teixeira; Lynne E Vinall; Dallas M Swallow
Journal:  Hum Genet       Date:  2003-08-27       Impact factor: 4.132

3.  Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Authors:  C Sanchez; R Chan; P Bajgain; S Rambally; G Palapattu; M Mims; C M Rooney; A M Leen; M K Brenner; J F Vera
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-01-08       Impact factor: 5.554

Review 4.  MUC1 and the immunobiology of cancer.

Authors:  Joyce Taylor-Papadimitriou; Joy M Burchell; Timothy Plunkett; Rosalind Graham; Isabel Correa; David Miles; Michael Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.698

5.  MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility.

Authors:  Cherry Yin-Yi Chang; Hui-Wen Chang; Chih-Mei Chen; Chia-Ying Lin; Chih-Ping Chen; Chih-Ho Lai; Wei-Yong Lin; Hsing-Ping Liu; Jim Jinn-Chyuan Sheu; Fuu-Jen Tsai
Journal:  BMC Med       Date:  2011-02-24       Impact factor: 8.775

6.  Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC.

Authors:  Xueliang Guo; Rhonda G Pace; Jaclyn R Stonebraker; Clayton W Commander; Anthony T Dang; Mitchell L Drumm; Ann Harris; Fei Zou; Dallas M Swallow; Fred A Wright; Wanda K O'Neal; Michael R Knowles
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

7.  Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy.

Authors:  Yuan-Feng Gong; Quan-Bo Zhou; Ya-Di Liao; Cong Mai; Tie-Jun Chen; Yun-Qiang Tang; Ru-Fu Chen
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

8.  Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations.

Authors:  Andrea Wenzel; Janine Altmueller; Arif B Ekici; Bernt Popp; Kurt Stueber; Holger Thiele; Alois Pannes; Simon Staubach; Eduardo Salido; Peter Nuernberg; Richard Reinhardt; André Reis; Patrick Rump; Franz-Georg Hanisch; Matthias T F Wolf; Michael Wiesener; Bruno Huettel; Bodo B Beck
Journal:  Sci Rep       Date:  2018-03-08       Impact factor: 4.379

9.  An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Authors:  C Heuser; M Ganser; A Hombach; H Brand; G Denton; F-G Hanisch; H Abken
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

10.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.